





|
|
What are the appropriate
screening tests for celiac disease?
The
tests of choice are antibody measurements in the blood,
ideally performed before the patient has removed gluten
from the diet. However, patients and physicians must
remember that no screening test is perfect, and that the
keys to confirming the diagnosis of CELIAC DISEASE
remain a small intestinal biopsy combined with the
patient’s subsequent clinical response to a gluten-free
diet. Thus, a patient (especially a young child) with
symptoms of CELIAC DISEASE should have a small bowel
biopsy, even if the antibodies are not highly
suggestive.
What are the different
antibody tests available? Can there be errors in
testing?
The
blood tests can be divided into 2 different types of
antibodies: those which are “anti-gluten”, and those
that “anti-self”. The “anti-gluten” antibodies are the
anti-gliadin IgG and IgA. Ig stands for
“immunoglobulin” or “antibody”. The “anti-self”
antibodies are anti-endomysial IgA and anti-tissue
transglutaminase IgA. The tissue transglutaminase IgA
antibody is often abbreviated as “tTG”. Each antibody
test varies widely in its sensitivity and specificity
for predicting whether the disease is present in any
individual. It must be remembered that NO test in
medicine is correct 100% of the time in each person!
There
are also several conditions which may yield false
negative antibody results. A false negative means that
the patient actually has the disease, but the test
result is negative. One of the conditions that may give
a false negative result is Immunoglobulin A or IgA
deficiency. If a patient has a low total IgA level, the
antibodies may be falsely low. This is why I always
recommend that a patient have a total IgA level drawn at
the same time the antibody testing is done. Young
children may not make the some of the “anti-self”
antibodies, as it takes a somewhat mature immune system
to make them. So in a young child, antiendomysial
antibody, or the TTG antibody, can have false negative
results. An inexperienced lab can misread the anti-endomysial
IgA test, which requires someone to read a slide through
a special microscope. It is possible that a celiac
patient could have a positive antibody test at one lab,
and a negative test at another. This is because
different labs may use different commercial test kits,
which vary in their sensitivity and specificity. And
lastly, a person has to be ingesting gluten at the time
the antibodies are drawn. A gluten-free diet will make
the antibody tests negative.
Let’s
discuss the different antibodies and what the strengths
and weaknesses are for each.
Antigliadin antibodies
The
antigliadin antibodies IgG and IgA recognize a small
piece of the gluten protein called gliadin. These
antibodies became available during the late 1970’s and
were the first step towards recognizing CELIAC DISEASE
as an autoimmune disorder. Antigliadin IgG has good
sensitivity, while antigliadin IgA has good specificity,
and therefore their combined use provided the first
reliable screening test for CELIAC DISEASE.
Unfortunately, many normal individuals without CELIAC
DISEASE will have an elevated antigliadin IgG, causing
much confusion among physicians. The antigliadin IgG is
useful in screening individuals who are IgA deficient,
as the other antibodies used for routine screening are
usually of the IgA class. It is thought that 0.2-0.4%
of the general population has selective IgA deficiency,
while 2 to 3% or more of celiacs are IgA deficient.
If a
patient’s celiac panel is only positive for antigliadin
IgG, this is not highly suggestive for CELIAC DISEASE if
the patient has a normal total IgA level, corrected for
age. Younger children make less IgA than older children
and adults. A markedly elevated antigliadin IgG, such
as greater than three to four times the upper limit of
normal for that lab, is highly suggestive of a condition
where the gut is leakier to gluten. This can happen in
food allergies, cystic fibrosis, parasitic infections,
Crohn’s disease, and other types of autoimmune GI
diseases. These antibodies may also be slightly
elevated in individuals with no obvious disease.
A
strength of the antigliadin antibodies is that they are
ELISA tests. ELISA is an abbreviation for
“enzyme-linked immunosorbent assay”. This is a rapid
immunochemical test that involves an enzyme, which a
protein that causes a biochemical reaction. An ELISA
test also involves an antibody or antigen.
ELISA tests are
utilized to detect substances that have antigenic
properties, primarily proteins, such as gliadin. The
importance of an ELISA test is that is it rapid,
inexpensive, and run by a machine. Thus the results are
independent of observer variability. The TTG test is
also an ELISA test. This is in contrast to the
antiendomysial IgA, where a slide has to be made, and a
person has to look at it through a microscope. These
are more prone to human error.
Antiendomysium antibodies
The
antiendomysial IgA antibody is an excellent screening
test for CELIAC DISEASE, with both a high sensitivity
and specificity. It is considered the gold standard of
antibodies. However, the subjective nature of this test
(someone still needs to look at the slide under a
microscope) may lead to false negative values and
unacceptable variability between laboratories. This
antibody was discovered in the early 1980’s, and rapidly
gained use as part of a screening “celiac panel” by
commercial labs in combination with antigliadin IgG and
IgA. Its major drawbacks are that it may be falsely
negative in young children, in patients with IgA
deficiency and a lesser degree of villous atrophy, and
in the hands of an inexperienced laboratory.
Tissue transglutaminase antibodies or TTG
Since
tTG had been first described as the autoantigen of
celiac disease in 1997, it has been utilized to develop
innovative diagnostic tools. The tTG IgA ELISA test is
highly sensitive and specific. The tTG assay correlates
well with EMA-IgA and biopsy. However, it represents an
improvement over the antiendomysial antibody assay
because it inexpensive, rapid, is not a subjective test,
and can be performed on a single drop of blood using a
dot-blot technique. One negative aspect of the TTG
antibody is that it can be falsely positive in a patient
who has another autoimmune condition. TTG false
positivity has been described in patients with both type
I diabetes and autoimmune hepatitis. Theoretically, it
can also be falsely positive in other autoimmune
disease.
|
|
|